Norges Bank
ARTV

Norges Bank’s Artiva Biotherapeutics ARTV Stock Holding History

Norges Bank’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-30,000
Closed -$302K – 1871
2024
Q4 		$302K Hold
30,000
– – ﹤0.01% 1815
2024
Q3 		$464K Buy
+30,000
New +$348K ﹤0.01% 1786

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Norges Bank's ARTV Position: Q1 2025 in Review

Norges Bank sold out of Artiva Biotherapeutics (ARTV) in Q1 2025, closing a stake of 30,000 shares — an estimated $302K sold.

Norges Bank first reported a position in ARTV in Q3 2024 and held it in 2 quarters. The position peaked at $464K in Q3 2024. 53 funds tracked by Wall St. Rank hold ARTV as of Q1 2025.

  • Norges Bank reported no remaining Artiva Biotherapeutics position as of Q1 2025 after selling out during the quarter.
  • Norges Bank sold 30,000 Artiva Biotherapeutics shares in Q1 2025, an estimated $302K.
  • Norges Bank first reported a position in Artiva Biotherapeutics in Q3 2024 and held it in 2 quarters.
  • Norges Bank's Artiva Biotherapeutics position peaked at $464K in Q3 2024.
  • 53 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q1 2025.

Based on Norges Bank's 13F filing for Q1 2025, filed 13 May 2025.